This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
The AMA and 118 other healthcare groups are urging CMS to finalize reforms that target prior authorization in Medicare Advantage plans that delay, deny and disrupt medically necessary care to patients.
In a survey by the Robert Wood Johnson Foundation from December 2022, 64.3% of adults in Medicaid-enrolled families were unaware of the resumption of Medicaid renewals in the future.
Hospitals and health systems have been facing financial pressures, with many experiencing negative operating margins. Workforce pressures in 2022, including staffing shortages and higher costs, have impacted the bottom line.
The program, UnitedHealthcare Rewards, encourages eligible members to use a compatible activity tracker, smartwatch or smartphone to meet daily activity goals, track sleep and measure other health goals.
“HHS is using every tool available to us to lower healthcare costs and increase access to high-quality, affordable healthcare,” says HHS Secretary Xavier Becerra.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
